Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 7/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | MYLK | Q15746 | 1/20 | 0.54 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.54 |
| ▸ | HSPH1 | Q92598 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707259 | 0.95 | LRRK2 (0.55) | LRRK2P2RX1TMPRSS4P2RX7P2RX4 | |
| SCHEMBL20280065 | 0.94 | LRRK2 (0.53) | LRRK2P2RX1TMPRSS4P2RX7P2RX4 | |
| SCHEMBL17858986 | 0.92 | LRRK2 (0.60) | LRRK2P2RX1TMPRSS4P2RX7P2RX4 | |
| SCHEMBL3497966 | 0.88 | LRRK2 (0.55) | LRRK2TMPRSS4MEN1KMT2AHSPH1 | |
| SCHEMBL6101699 | 0.87 | LRRK2 (0.52) | LRRK2P2RX1P2RX7P2RX4CYP1A2 | |
| SCHEMBL14886070 | 0.87 | LRRK2 (0.74) | LRRK2P2RX1TMPRSS4P2RX7P2RX4 | |
| SCHEMBL17858984 | 0.87 | LRRK2 (0.55) | LRRK2P2RX1TMPRSS4MEN1KMT2A | |
| SCHEMBL16702757 | 0.86 | P2RX1 (0.67) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL3498785 | 0.85 | TMPRSS4 (0.57) | LRRK2TMPRSS4HSPH1CYP1A2CYP2C19 | |
| SCHEMBL19862002 | 0.83 | P2RX1 (0.62) | P2RX1TMPRSS4P2RX7P2RX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11071744-B2 | Prodrug salts | AEROMICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200297740-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3065727-B1 | NOVEL PRODRUG SALTS | AEROMICS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10258636-B2 | Prodrug salts | AEROMICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180169118-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9949991-B2 | Methods of treating aquaporin-mediated conditions | AEROMICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160264604-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264604-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20150342967-A1 | METHODS | AEROMICS, INC. | 2015-12-03 | — | — | US | disclosed |
| WO-2015069961-A1 | NOVEL PRODRUG SALTS | AEROMICS, LLC (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133405-A1 | Methods | AEROMICS, INC. | 2015-05-14 | — | — | US | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342967-A1 | METHODS | AQP4, AQP1, AQP3 | LRRK2 2061/4885P2RX1 2910/4885TMPRSS4 1257/4885 |
| US-20200297740-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | LRRK2 4315/4885P2RX1 543/4885TMPRSS4 1033/4885 |
| US-20180169118-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | LRRK2 4315/4885P2RX1 543/4885TMPRSS4 1033/4885 |
| US-20160264604-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | LRRK2 4315/4885P2RX1 543/4885TMPRSS4 1033/4885 |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | LRRK2 4237/4885P2RX1 2507/4885TMPRSS4 4278/4885 |
| US-10258636-B2 | Prodrug salts | AQP4, AQP1, AQP3 | LRRK2 4324/4885P2RX1 556/4885TMPRSS4 1144/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | LRRK2 2389/4885P2RX1 2805/4885TMPRSS4 946/4885 |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | LRRK2 4315/4885P2RX1 543/4885TMPRSS4 1033/4885 |
| US-20150133405-A1 | Methods | AQP4, AQP1, AQP3 | LRRK2 2061/4885P2RX1 2910/4885TMPRSS4 1257/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | LRRK2 2356/4885P2RX1 3644/4885TMPRSS4 3984/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | LRRK2 1814/4885P2RX1 3317/4885TMPRSS4 1444/4885 |
| US-11071744-B2 | Prodrug salts | AQP4, AQP1, AQP3 | LRRK2 4324/4885P2RX1 556/4885TMPRSS4 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.